CNS Response: The key to informed mental health treatment

Brean Murray Initiates Coverage on CNS Response (CNSO) with a "Buy" rating
January 14, 2008

January 14, 2008 9:28 AM EST - Brean Murray initiates coverage on CNS Response (OTCBB: CNSO) with a Buy rating, citing its "proprietary rEEG technology that has proven effective" in 70% of patient treatments, compared to an industry average of less than 35%.

 

CNS Response, Inc., a life sciences company, focuses on the commercialization of a patented system that aids psychiatrists and other physicians in the identification and determination of appropriate medications for patients with certain behavioral disorders.

Back to News and Press